|Synta Pharmaceuticals Corp.|
45 Hartwell Avenue
United States - Map
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its lead drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; and in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer. The companys product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; and Elesclomol, a mitochondria-targeting agent that is in Phase 2 clinical trial for ovarian cancer. Its product pipeline in preclinical development stage for inflammatory diseases includes CRACM ion channel inhibitors for rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergy, transplant rejection, and other autoimmune diseases and inflammatory conditions; and IL-12/23 inhibitors for inflammatory and autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.
|Synta Pharmaceuticals Corp.’s ISS Governance QuickScore as of Apr 1, 2014 is 8. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Keith R. Gollust ,
Exec. Chairman of The Board, Chairman of Nominating and Governance Committee, Chairman of Exec. Committee, Member of Audit Committee and Member of Compensation Committee
|Dr. Lan Bo Chen Ph.D.,
|Mr. Keith S. Ehrlich CPA,
Chief Financial Officer, Principal Accounting Officer and VP of Admin. & Fin.
|Ms. Wendy E. Rieder Esq.,
VP of Intellectual Property & Legal Affairs, Gen. Counsel and Sec.
|Dr. Vojo Vukovic M.D., Ph.D.,
Chief Medical Officer and Sr. VP of Clinical Research & Regulatory Affairs
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|